{
    "nctId": "NCT04276337",
    "briefTitle": "Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy",
    "officialTitle": "Genetic Characteristics of HER2 Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP) Regimen",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Breast Cancer, Chemotherapy Effect, Circulating Tumor DNA",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "pathologic complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HER2+ Breast cancer\n* Stage IIA - IIIC\n* Plan to receive neoadjuvant chemotherapy with docetaxel, carboplatin, herceptin, perjeta\n* Sign to informed consent\n\nExclusion Criteria:\n\n* Double primary cancer",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}